Navigation Links
SCOLR Pharma, Inc. Announces Intention to Voluntarily Delist From NYSE AMEX Exchange
Date:12/22/2010

ing statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning the anticipated timing of effectiveness of the delisting of SCOLR's common stock from the Exchange, the anticipated quotation of our common stock on the OTC Bulletin Board and the orderliness and timing of the transition of trading in its common stock.  These forward-looking statements involve risks and uncertainties, including activities, events or developments that SCOLR expects, believes or anticipates will or may occur in the future. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including our failure or the failure of others to timely comply with applicable rules of the Exchange, the SEC, the OTC Bulletin Board or the Financial Industry Regulatory Authority (FINRA). For example, SCOLR must rely on market makers to submit an application to permit quotation of its common stock on the OTC Bulletin Board.  If such application is not accepted, or is not timely filed, SCOLR's efforts to transition the trading of its common stock on the OTC Bulletin Board may be delayed or unsuccessful.  Additional assumptions, risks and uncertainties related to SCOLR's business are described in detail in its registration statements, reports and other filings with the Securities and Exchange Commission, including the "Risk Factors" set forth in its Annual Report on Form 10-K, as supplemented by its quarterly reports on Form 10-Q. Such filings are available on SCOLR's website or at www.sec.gov.  You are cautioned that such statements are not guarantees of future performance and that actual result or developments may differ materially from those set forth in the forward-looking statements. SCOLR undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events o
'/>"/>
SOURCE SCOLR Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen
2. SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results
3. SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results
4. SCOLR Pharma, Inc. Receives Notices From NYSE Amex LLC Regarding Compliance Plan and Listing Standards
5. SCOLR Pharma, Inc. Licenses Dietary Supplements
6. SCOLR Pharma, Inc. Enters into Worldwide Licensing Agreement with RedHill Biopharma Ltd.
7. SCOLR Pharma, Inc. Signs Agreement with The Emerson Group to Provide Sales Support for Nutritional & OTC Products
8. SCOLR Pharma, Inc. Names Carl Johnson as Chairman; Former Chairman Michael Taglich Remains as Director
9. SCOLR Pharma, Inc. Reports Third Quarter 2010 Financial Results
10. Victory Pharma, Inc. Reports MGX006 Enters Into Pivotal Development Program
11. CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... Sept. 23, 2014 CASI Pharmaceuticals, Inc. (Nasdaq: ... the acquisition, development and commercialization of innovative therapeutics addressing ... market with a primary focus on China ... Shrotriya , MD, Chairman and Chief Executive Officer of ... appointment was made in connection with the recently announced ...
(Date:9/23/2014)...  Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the ... address unmet medical needs in the areas of ... has appointed Rasappa Arumugham , PhD, as ... has over 25 years of diverse experience in ... of formulation research, analytical method development, quality control ...
(Date:9/23/2014)... Sept. 23, 2014  As physicians seek information ... communication channels to learn about new therapies or ... from a new report by global sales and ... that communicating via a customized mix of digital ... best opportunity to engage with physicians. And, productive ...
Breaking Medicine Technology:CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 2CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 3CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 4Soligenix Appoints Rasappa Arumugham, PhD, as Vice President of Biopharmaceutical Development 2Soligenix Appoints Rasappa Arumugham, PhD, as Vice President of Biopharmaceutical Development 3Soligenix Appoints Rasappa Arumugham, PhD, as Vice President of Biopharmaceutical Development 4As sales reps see doors close for in-person visits with physicians, digital doors open communication 2As sales reps see doors close for in-person visits with physicians, digital doors open communication 3As sales reps see doors close for in-person visits with physicians, digital doors open communication 4As sales reps see doors close for in-person visits with physicians, digital doors open communication 5
(Date:9/23/2014)... Avid collector Andrew Hawley, from Vintage Rock ... Auditorium Seattle concert posters. The Doors were a smash hit ... year. The Seattle Eagles Auditorium concert was held on July ... to Eagles Auditorium in November the same year. The artist ... comes in three colors. The poster is a split fountain ...
(Date:9/23/2014)... News) -- Few children who take medication for ... the rates vary six-fold across counties in the ... alone can manage symptoms for many children with ... receive behavioral therapy (psychotherapy), the Rand Corp. researchers ... than 1,500 counties across the United States that ...
(Date:9/23/2014)... national report showing the benefits of preventing a ... Medicaid services was released today by the American ... Congress Must Save the Medicaid Primary Care Pay ... Access to Life-Saving Primary Care Will Expire," explains ... access to internists and pediatricians (and their related ...
(Date:9/23/2014)... Texas (PRWEB) September 23, 2014 ... for allergic rhinitis (AR) is highly fragmented, ... different SIT formulations available, under different regulatory ... between markets. Europe has the most developed ... (SLIT), and allergen immunotherapy tablets (AITs) all ...
(Date:9/23/2014)... York, New York (PRWEB) September 23, 2014 ... forward in courts around the country, Bernstein Liebhard LLP ... Court, Middle District of Florida on September 19th, the ... from a case filed in that jurisdiction on behalf ... growth) and other complications due to his use of ...
Breaking Medicine News(10 mins):Health News:Kids Taking ADHD Drugs Get Little Psychotherapy: Study 2Health News:Unless Congress acts, patients may soon lose access to primary care 2Health News:Unless Congress acts, patients may soon lose access to primary care 3Health News:Allergen extract Allergic Rhinitis Specific Immunotherapy Market to Grow $688.3m by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:Allergen extract Allergic Rhinitis Specific Immunotherapy Market to Grow $688.3m by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:Allergen extract Allergic Rhinitis Specific Immunotherapy Market to Grow $688.3m by 2018 Says a New Report Available at MarketOptimizer.org 4Health News:Risperdal Lawsuit News: Fraud, Negligence Per Se Claims Dismissed from Florida Complaint, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuit News: Fraud, Negligence Per Se Claims Dismissed from Florida Complaint, Bernstein Liebhard LLP Reports 3
... The makers of the WaveSense(TM) line of blood ... commitment to providing low cost, high accuracy, and high ... diabetes. The WaveSense Presto(TM) BGM can be found at ... strips (50 ct) are often as low as $22.88, ...
... The Hazelden Foundation, one of the world,s largest and ... centers, announced today that the Rev. Michael J. O,Connell ... of Trustees. O,Connell succeeds Norbert J. Conzemius, who served ... http://www.newscom.com/cgi-bin/prnh/20061128/CGTU038LOGO ) , , "The Rev. O,Connell ...
... -- GHX honored 12 healthcare provider and supplier ... chain performance. The awards were presented on Wednesday, June 3, ... Annual GHX Supply Chain Summit - the largest forum in ... of the healthcare supply chain. , , The theme ...
... in Under 4 years , , PLEASANTON, Calif., June ... Photopneumatic system in the United States. The installation of the ... base to approximately 1800 systems worldwide. The company has direct ... of distributors in over 20 countries in Asia, Europe and ...
... , , ... ANDS ) announced that it has entered into ... in gross proceeds in a "registered direct" offering through the ... estimates that net proceeds from the offering will be approximately ...
... 4 As the administration moves forward with health care ... research released this week by the Deloitte Center for Health ... Diego highlights how comparative effectiveness and consumerism will challenge the ... , During a time when the majority of U.S. consumers ...
Cached Medicine News:Health News:WaveSense Reduces Diabetes Testing Cost by 50% 2Health News:The Rev. Michael J. O'Connell Assumes Chairmanship of Hazelden Foundation Board of Trustees 2Health News:GHXcellence Awards Honor Healthcare Providers and Suppliers for Achievements in Supply Chain Performance 2Health News:GHXcellence Awards Honor Healthcare Providers and Suppliers for Achievements in Supply Chain Performance 3Health News:Aesthera Announces Installation of 1000th Photopneumatic System in US 2Health News:Anadys Pharmaceuticals, Inc. Announces Pricing of Common Stock and Warrant Offering 2Health News:Anadys Pharmaceuticals, Inc. Announces Pricing of Common Stock and Warrant Offering 3Health News:Health Plans Prepare for Health Care Reform: Comparative Effectiveness, Consumerism Drive Future Changes, According to Deloitte Study 2Health News:Health Plans Prepare for Health Care Reform: Comparative Effectiveness, Consumerism Drive Future Changes, According to Deloitte Study 3Health News:Health Plans Prepare for Health Care Reform: Comparative Effectiveness, Consumerism Drive Future Changes, According to Deloitte Study 4Health News:Health Plans Prepare for Health Care Reform: Comparative Effectiveness, Consumerism Drive Future Changes, According to Deloitte Study 5
... HIV-1 Antibody Test (Reveal Test) is MedMiras ... antibodies in human serum or plasma against ... in response to HIV infection. The Reveal ... membrane technology, and is comprised of a ...
... The OraQuick ADVANCE Rapid ... a single-use, qualitative immunoassay ... Human Immunodeficiency Virus Type ... 2 (HIV-2) in oral ...
... The advanced performance benefits ... been applied to the ... Implants) Upper Extremity Plates. ... combine to provide a ...
... of TiMAX material have been applied to a ... and an ultra-low profile combine to provide a ... extremity. , ,This complete set of periarticular plates ... , Fibula Composite Plate , Spider ...
Medicine Products: